cyrilzakka/clinical-trials huggingface dataset:
Electromagnetic Field Protection Device Use Impact in Healthy Volunteers

This is a prospective, single group, self-controlled study to evaluate the clinical and molecular impact of continuous in-home resonance-based electromagnetic field (EMF) protection device usage in healthy individuals.


Eligibility Criteria:
Inclusion Criteria:

* Any sex, gender orientation, and ethnicity
* Between ages 30 and 70
* Must be willing and able to participate in venipuncture, health history and clinical assessments, passive monitoring (Oura ring), and continuous in-home Blushield device usage

Exclusion Criteria:

* Significant change in diagnosis and/or treatment of major illness or injury within 2 years prior to screening, e.g., diabetes, cancer, cardiovascular disease, psychiatric condition 2. Any ongoing immune system concerns or immunodeficiency disease
* History of any viral illness in preceding year
* Body mass index (BMI) \> 35 kg/m2
* Presence of active infection
* Any other illness, disorder, alcohol or chemical dependence that in the opinion of investigators would render study participation unsuitable
* Unable or unwilling to provide required biological sample
* Unable or unwilling to avoid pregnancy during study period
Long Term Outcome of Hypospadias Repair

Hypospadias is a common congenital abnormality of the penis which affects approximately 1 boy in 250. The opening of the urethra is located on the undersurface of the penis rather than the tip,the foreskin is deficient and there is curvature of the penile shaft in more severe cases. Although the most commonly practised corrective operation ( TIP procedure) gives generally good results, recently published evidence points to a possible long term risk of stenosis ( narrowing of the reconstructed urethra). This comparative study will combine clinical assessment with non invasive measurements of urinary flow to assess the functional outcome of a large series of patients who have undergone hypospadias surgery . The study is primarily designed to answer this question : does a modification of the standard operation which incorporates a skin graft into the reconstructed urethra lead to improved urinary flow and a decreased risk of stenosis? This has not been previously studied . The findings of our study could make an important contribution to improvements in the surgical treatment of boys born with hypospadias.


Eligibility Criteria:
Inclusion Criteria:

- 1 Patients with hypospadias who have been treated one of the following two surgical proceduresStandard Tubularised Incised Plate (TIP) operation (Group A) or Tubularised Incised Plate (TIP) procedure incorporating a free graft of preputial skin (in a layer of foreskin) into the urethral reconstruction (Group B ) 2 The study will be confined to primary operations. Patients in whom either of the techniques was used for a secondary or 'redo' procedure will be excluded from the study.

3 The study will be confined to boys over 3 years of age who are potty trained and able to pass urine for the non invasive flow rate test .

Exclusion Criteria:

- 1 Patients whose hypospadias was corrected using some technique other than 'standard' or 'grafted' TIP repair.

2 "Redo" cases 3 Boys under 3 years at the time of the study or patients who do not have full bladder control for some other reason.
EXplanted LIver and Ex-vivo Pancreatic Specimen Evaluation by 7 TESLA MRI

Aim of this study is to evaluate the correlation between the characteristics detected by the 7T MRI equipment and the histological composition of native explanted livers (group A), liver graft excluded for donation (group B) and surgical specimens of primary pancreatic tumour, which underwent pancreaticoduodenectomy (group C).


Eligibility Criteria:
GROUP A of Native Liver

Inclusion Criteria:

* informed consent
* full possession of one's faculties
* patients who are going to undergo liver transplantation, independently from previous therapy or from the primary disease they are affected by.

Exclusion Criteria:

* patients affected by polycystic liver disease
* excluded from liver transplantation.

GROUP B of Excluded Grafts

Inclusion Criteria:

- liver grafts with histologically proven macrovescic steatosis, not fit for transplantation

Exclusion Criteria:

* liver grafts histologically proven macrovescic steatosis fit for transplantation
* liver grafts not fit for transplantation due to causes other than steatosis

GROUP C of Focal Pancreatic Lesion

Inclusion Criteria:

* informed consent
* full possession of one's faculties
* pancreatic lesion assessed by CT examination and histologically proved, which are candidates for pancreaticoduodenectomy or total pancreatectomy

Exclusion Criteria:

- excluded from surgery due to the severity of their condition.
Information Needs Around Parenteral nUTrition in Cancer

This study will explore the information needs of patient's with advanced cancer, and their carers, when making a decision to commence or discontinue parenteral nutrition. Interviews will be conducted with both patients with advanced cancer, and their carers to determine the information they need to make a shared decision with the healthcare team.

Parenteral nutrition (PN) is a type of nutritional liquid that is given directly into a vein, and is usually given when a person does not have a working gut. This type of nutrition is managed by a team of healthcare professionals and requires regular monitoring, such as bloods tests, to allow the team to provide the right balance of nutrients to the individual patient. This is an important decision, and the benefits, risks and consequences of having this type of nutrition should be fully explained to the patient and carer, to make sure they can make an informed decision. The aim of this study is to find out what information both patients and carers feel they need to be able to make a decision to start, and a later date stop, parenteral nutrition, with a diagnosis of advanced (incurable) cancer.

It is not clear if patients and carers get all the information they need before making this decision, and often the decision is made by a doctor and other healthcare professionals. However, patients and carers have a right to make decisions about their care. We will therefore interview patients and carers who have experience of making this decision, or in the process of making this decision, to find out what information is important to them. Our aim is to use the results from this research to improve the experience that patients and carers have in the future.

Eligibility Criteria:
Inclusion Criteria:

* Adults aged 18 years and over
* Fluent English speaker
* Is aware of diagnosis of advanced cancer
* Patient considering starting PN, is currently receiving PN or has previously received PN OR
* Carer of a patient considering, receiving or who has received PN
* NHS patient
* Assessed as having capacity to give consent and participate
* Current patient at one of the recruiting hospital sites

Exclusion Criteria:

* Private patients
The Effect of the Use of BATHE Interview Technique on Treatment Compliance in Hypertension Patients in Primary Care

The research is planned to evaluate the treatment compliance after the BATHE interview technique in hypertension patients.

In order to be evaluated for suitability for the study, patients aged 18-80 who have been diagnosed with hypertension for at least 6 months (n= 220) were interviewed and 86 hypertension patients who met the inclusion criteria and volunteered for the study were included in the study. Participants whose eligibility was determined as a result of the evaluation in terms of inclusion and exclusion criteria were asked about their volunteerism in the intervention study, their written consent was obtained from those who volunteered, and those who volunteered were randomized.

Eligibility Criteria:
Inclusion Criteria:

* Being a patient of hypertension
* Be over 18 years old
* Be less than 80 years old
* To have been diagnosed for at least 6 months
* Volunteering
* To be able to use any of the online video calling channels

Exclusion Criteria:

* Communication problem
* Presence of psychiatric illness and/or use of psychiatric medication
* Pregnancy
Predictive Values of Serum Adiponectin Levels in Aneurysmal Subarachnoid Hemorrhage.

The purpose of this study is to evaluate the predictive value of serum adiponectin levels in aneurysmal subarachnoid hemorrhage patients.

Adiponectin (APN) is an abundant protein hormone derived from adipose tissue. It has been suggested to exert anti-inflammatory, antiatherogenic, and vascular protective. Subarachnoid hemorrhage (SAH) comprises about 5% of all strokes with high mortality and permanent disability rates. Although many patients survive from the initial hemorrhage or rebleeding, they suffered from long-term delayed neurological deficits (DNDs), including stroke, delayed cerebral ischemia, cognitive and neuropsychological abnormalities that seriously impact overall function and quality of life. Ruptured cerebral aneurysms are the most common cause of SAH. There is growing evidence supporting APN act as a predictive factor for SAH. The observational study will focus on the predictive value of serum adiponectin levels in aneurysmal subarachnoid hemorrhage (aSAH).

Eligibility Criteria:
Inclusion Criteria:

* Age\>18yrs and age\<90yrs
* It shows subarachnoid hemorrhage (SAH) based on computed tomography (CT) scan on admission
* Aneurysmal subarachnoid hemorrhage confirmed by computed tomography angiography (CTA), magnetic resonance angiography (MRA) or digital subtraction angiography (DSA)
* SAH grade is assessed by Hunt \& Hess classification
* Informed consented

Exclusion Criteria:

* Traumatic subarachnoid hemorrhage
* Patients with cerebral herniation or highly possible to occur within 2 days from SAH
* Length of hospital stay is expected to be less than 5 days
* Duration from onset to admission is more than 48 hours
* Disturbance of communication or poor compliance to blood collection, imaging examination and follow-up
Attention Training Trial

This study aims to examine the effects of smartphone-based Attention-Bias Modification Training (ABMT) in chronic pain participants.


Eligibility Criteria:
Inclusion Criteria:

* existing chronic pain condition

Exclusion Criteria:

* None
Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.

The present clinical trial is a dose comparison of a multi-component active immunotherapy designed to stimulate an immune reaction to specific tumor associated antigens which are highly expressed on a large number of solid cancers.

The majority of tumors are ignored by the immune system and it was thought for a long time that tumor antigens did not exist. However, recently a number of tumor antigens have been described. These antigens reside on cancer cells and can be recognized by specific T-cells which can ultimately attack and destroy the tumor.

Eligibility Criteria:
Inclusion Criteria:

18 years of age or older Advanced, refractory solid malignancy that is histologically proven Measurable disease ECOG performance status of 0, 1 or 2 Adequate bone marrow reserve as evidenced by a Absolute neutrophil count (ANC) = 1,500/microL; Platelet count = 100,000/microL Adequate renal and hepatic function as evidenced by a serum creatinine = 1.5 mg/dL; Serum total bilirubin = 2.0 mg/dL; Alkaline phosphatase = 3X the ULN for the reference lab (= 5 the ULN for the reference lab for subjects with known hepatic metastases); SGOT/SGPT = 3X the ULN for the reference lab (= 5 the ULN for the reference lab for subjects with known hepatic metastases)

Exclusion Criteria:

Symptomatic central nervous system (CNS) metastases Any autoimmune disorder Positive HIV, hepatitis B or hepatitis C antibody test Any allogeneic transplant Congestive heart failure Affected inguinal lymph nodes (metastatic process) or lack inguinal lymph nodes (resection)
A Prospective Randomized Trial of Efficacy of Stump Closure for Distal Pancreatectomy

Overall morbidity rate remained high after distal pancreatectomy (DP), ranging from 30% to 60%. Whilst postoperative pancreatic fistula (POPF) remains serious and also is one of the most common complications after DP (12% to 40%). POPF after DP is also associated with major complications such as bleeding or septic shock and remains an equivocal problem. However, all the previous reports were retrospective review, non-randomized study, or individual experience and showed no significant improvement of overall POPF. As always, this issue remains in obscurity and seek for a more concrete evidence to solve.

Pancreatic surgery has been called formidable operation not only the technical challenge to surgeons but also demanding for patients. It evolved into a safe procedure with mortality rates of \<5% recently, cutting down gradually from 25% in the 1960s. However, overall morbidity rate remained high ranging from 30% to 60%.

Distal pancreatectomy (DP) has been believed a safer and minor procedure compared with pancreatic head resection including standard pancreaticoduodenectomy (PD), pylorus-preserving pancreaticoduodenectomy (PPPD), or duodenum-preserving pancreatic head resection (DPPHR). Whilst postoperative pancreatic fistula (POPF) remains serious and also is one of the most common complications after DP. Büchler et al observed that the POPF rate was in fact significantly higher after DP when compared to pancreatic head resections. The variable documented incidence of POPF following DP ranges from 12% to 40%. POPF after DP is also associated with major complications such as bleeding or septic shock and remains an equivocal problem.

Although the majority of complications are not life-threatening, POPF could prolong hospitalization, expend expenditure for healthcare, abrade the quality of life; moreover, delay in further management for a fraction of patients with malignancy. Over the past two decades, various risk factors and multitudinous operative procedures have been held for reduction POPD following DP. These include underlying disease process, method of stump closure, and concomitant splenectomy However, all these reports were retrospective review, non-randomized study, or individual experience. As always, this issue remains in obscurity and seek for a more concrete evidence to solve.

Eligibility Criteria:
Inclusion Criteria:

* age\>= 20 years
* scheduled distal pancreatectomy at NTUH
* unable to realize this trial and willing to sign the informed consent form

Exclusion Criteria:

* age\< 20 years, pregnent women, breast-feeding women, or mentally illed
* active malignancy within 2 years
* received other upper abdomen major surgery
* scheduled spleen preservation or associated major organ resection
The Effect of Sitting and Standing Posture on Trunk Rotation in Patients With Idiopathic Scoliosis

The aim of this study is to investigate the acute effect of activities of daily living on trunk rotation in patients with adolescent idiopathic scoliosis.

Patients with AIS who applied to Bandırma Onyedi Eylül University Physiotherapy and Rehabilitation Department will be included in this study.

Individuals diagnosed with AIS, whose Cobb angle is between 20º -50º, who do not have any chronic diseases that require neurological or psychiatric medication, and who volunteer to participate in the study will be included. Individuals with any contraindications for exercise, previous spine surgery, thoracic apex curvature of 6 or more, mental problems, non-idiopathic scoliosis but with different causes will be excluded from the study.

To determine the demographic characteristics of the participants, age, gender, weight, height, presence of chronic disease, age at first diagnosis, exercise habits, treatments, and brace use will be questioned. The ATR will be used to measure degrees of trunk rotation to monitor the effects of treatment without radiographic evaluation.

On the first day, the demographic characteristics of the participants will be questioned, Cobb angles, Risser findings, and ATR degrees will be recorded. After the first day, all postural activities and measurements will be taken on different days (at least three days apart) not to affect the degrees of trunk rotation in patients with AIS.

Eligibility Criteria:
Inclusion Criteria:

* Being diagnosed with AIS between the ages of 10-35
* Cobb angle between 20º -50º,
* To be able to continue the program to be applied,
* Not having a chronic disease that requires the use of any neurological or psychiatric medication,
* The willingness of parents and/or patients to participate in the study.

Exclusion Criteria:

* The patient has any contraindications for exercise,
* Having had previous spine surgery,
* Having a curvature of 6 or more thoracic apex,
* Having any mental problems,
* The fact that scoliosis is not idiopathic but has arisen for different reasons (neurological, congenital, etc.)
Gene Expression Analysis of Patients With Metastatic Colorectal Cancer Receiving Oxaliplatin Based Chemotherapy Regimen

1.1 To collect pathological tumor specimens of patients with metastatic colorectal cancer in a prospective fashion for correlative studies of response to an oxaliplatin based chemotherapy regimen.

1.2 To determine a gene expression profile that predicts response to an oxaliplatin based chemotherapy regimen in this cohort of patients.

This is a single-arm, non-randomized trial of oxaliplatin and capecitabine. Patients that are placed on other studies that utilize the same chemotherapy regimen can enter this study. Those patients will be treated according to the clinical study on which they have been entered. For patients not on another clinical trial, the treatment outlined below should be followed.

Eligibility Criteria:
Inclusion Criteria:

* All patients, \>18 years of age, with metastatic/recurrent colorectal cancer are eligible.
* Patients must have a life expectancy of at least 12 weeks.
* Patients must have a Zubrod performance status of 0-2.
* Patients must sign an informed consent.
* Patients should have adequate bone marrow function defined by an absolute peripheral granulocyte count of \> 1,500 or cells/mm3 and platelet count \> 100,000/mm3 and absence of a regular red blood cell transfusion requirement.
* Patients should have adequate hepatic function with a total bilirubin \< 2 mg/dl and SGOT or SGPT \< two times the upper limit of normal, and adequate renal function as defined by a serum creatinine \< 1.5 x upper limit of normal.
* The patient must agree to a biopsy of a sample of tumor for correlative studies.
* The patient is an appropriate candidate for oxaliplatin/capecitabine based chemotherapy.
* The patient must have measurable disease.

Exclusion Criteria:

* Patients with symptomatic brain metastases are excluded from this study.
* Pregnant women or nursing mothers are not eligible for this trial. Patients of child bearing potential must use adequate contraception.
* Patients may receive no other concurrent chemotherapy or radiation therapy during this trial.
* Patients with severe medical problems such as uncontrolled diabetes mellitus or cardiovascular disease or active infections are not eligible for this trial.
* Patients may not have received oxaliplatin previously.
* Patients with a prior unanticipated severe reaction to fluoropyrimidine therapy, or known dihydropyrimidine dehydrogenase (DPD) deficiency, or known hypersensitivity to platinum compounds or any of the components of the study medications.
Normative Database for Gait Analysis on the GRAIL UZ Gent

The aim of this study is to collect a large set of norm/control data on an instrumented treadmill (the Gait Real-time Analysis Interactive Lab - GRAIL) at the university hospital of Ghent for the purpose of clinical studies as well as for clinical interpretation.

We hypothesize that this norm/control data will provide reference data of the normal gait patterns in the healthy population such that we can then use it to identify gait abnormalities in populations with pathology.

The following data will be collected on the GRAIL while subjects walk at different gait speeds: 3D kinematics, kinetics, and EMG.

Additionally, 3D kinematics, kinetics, and EMG data will be collected when performing either a cognitive (Stroop Color and Word Test) or motor (requiring arm swing) dual-task while walking at comfortable walking speed.


Eligibility Criteria:
Inclusion Criteria:

- Healthy participants

Exclusion Criteria:

* They suffer from neurological disorder
* Have balance problems
* Take medications that affect gait and balance
* Have undergone surgical procedures on the lower limbs in the past
* Experience pain in their lower limbs or back at the time of test taking.
Relation Between the Value of Platelet Clot Stiffness (PCS) Obtained by Sonorheometric Method of Delocalized Hemostasis (QUANTRA®), and the Presence of a Disorder of Primary Hemostasis, in Cardiac Surgery Patients. PLAQUA-Study

The goal of this study is to determine whether the Platelet Clot Stiffness (PCS) measured by QUANTRA® is predictive of an abnormality in primary haemostasis intraoperatively in cardiac surgery performed under extracorporeal circulation.

The aim is to compare the assessment of platelet function by QUANTRA® (data called PCS, obtained in around ten minutes) with laboratory tests which are validated, but which cannot be used in current practice (response time too long, in particular). We are therefore seeking to determine whether QUANTRA is reliable in the search for a primary hemostasis anomaly, defined by significant thrombocytopenia (platelet count below 100G/L), and/or a prolongation of platelet occlusion time measured by PFA-200® (normal or increased).

This clinical research project will last 12 months. It will take place in the cardiac surgery operating room at CHU Félix Guyon, and will involve 100 patients.

Patients who have consented to participate in this research project will be managed in the operating room in the usual way, with no change to their usual care (in terms of treatments received). At the end of the surgery, we will add 3 blood samples (maximum 8.1ml) for analysis to assess platelet function and compare with QUANTRA data.

This blood sample will be the only procedure performed. Medical management remains standard and will not be disrupted by this test.


Eligibility Criteria:
Inclusion Criteria:

Patients

* Hospitalized for scheduled cardiac surgery performed under extracorporeal circulation, including coronary bypass, valve replacement, aortic arch and combined surgeries.

Exclusion Criteria:

Patients:

* with preoperative hematocrit \< 35% and preoperative platelet count \< 80,000 G/L (validity of PFA-200® Test)
* With known congenital or acquired Willebrand's disease, or known platelet dysfunction.
* On double antiaggregation, not discontinued at the time of surgery
* Vulnerable patients: minors or protected adults, pregnant women, patients not affiliated to the social security system.
* Emergency situation